- Home
- NFBK vs MNMD Comparison
NFBK vs MNMD Comparison
Compare NFBK & MNMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NFBK
- MNMD
- Stock Information
- Founded
- NFBK 1887
- MNMD 2019
- Country
- NFBK United States
- MNMD United States
- Employees
- NFBK N/A
- MNMD N/A
- Industry
- NFBK Major Banks
- MNMD Pharmaceuticals and Biotechnology
- Sector
- NFBK Finance
- MNMD Health Care
- Exchange
- NFBK Nasdaq
- MNMD Nasdaq
- Market Cap
- NFBK 482.5M
- MNMD 509.2M
- IPO Year
- NFBK 2007
- MNMD N/A
- Fundamental
- Price
- NFBK $10.88
- MNMD $9.76
- Analyst Decision
- NFBK Buy
- MNMD Strong Buy
- Analyst Count
- NFBK 2
- MNMD 6
- Target Price
- NFBK $13.00
- MNMD $24.67
- AVG Volume (30 Days)
- NFBK 174.5K
- MNMD 1.3M
- Earning Date
- NFBK 07-23-2025
- MNMD 07-31-2025
- Dividend Yield
- NFBK 4.78%
- MNMD N/A
- EPS Growth
- NFBK 28.89
- MNMD N/A
- EPS
- NFBK 0.86
- MNMD N/A
- Revenue
- NFBK $133,079,000.00
- MNMD N/A
- Revenue This Year
- NFBK $8.33
- MNMD N/A
- Revenue Next Year
- NFBK $15.77
- MNMD N/A
- P/E Ratio
- NFBK $12.62
- MNMD N/A
- Revenue Growth
- NFBK 4.86
- MNMD N/A
- 52 Week Low
- NFBK $9.40
- MNMD $4.70
- 52 Week High
- NFBK $14.39
- MNMD $10.44
- Technical
- Relative Strength Index (RSI)
- NFBK 33.02
- MNMD 71.46
- Support Level
- NFBK $11.18
- MNMD $9.54
- Resistance Level
- NFBK $11.57
- MNMD $10.09
- Average True Range (ATR)
- NFBK 0.27
- MNMD 0.47
- MACD
- NFBK -0.08
- MNMD 0.18
- Stochastic Oscillator
- NFBK 2.94
- MNMD 83.89
About NFBK Northfield Bancorp Inc. (Delaware)
Northfield Bancorp Inc is the holding company for Northfield Bank. Its subsidiary provides banking services to individuals and corporate customers in Richmond and Kings Counties in New York, and Hunterdon, Mercer, Union and Middlesex counties in New Jersey. The bank attracts deposits and offers credit and other banking services.
About MNMD Mind Medicine (MindMed) Inc.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).